Europe Diabetic Foot Ulcer Treatment Market To Reach $2.32 Billion By 2030

Europe Diabetic Foot Ulcer Treatment Market Growth & Trends

The Europe diabetic foot ulcer treatment market size is expected to reach USD 2.32 billion by 2030, registering a CAGR of 5.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. Diabetes is one of the major causes of amputation, blindness, stroke, end-stage renal failure, kidney failure, and heart attacks in this region. According to the International Diabetes Federation, ~66 million people were suffering from diabetes in Europe in 2017. The number is expected to increase to ~81 million by 2045. The mortality rate associated with DFU is ~5% in the first 12 months and increases up to 42% by the end of 5 years. Many adjuvant therapies, such as nonsurgical debridement agents, dressings & topical agents, oxygen therapies, negative pressure wound therapy, acellular bioproducts, human growth factors, energy-based therapies, and systemic therapies, are said to effectively improve and cure DFU.

Recent studies suggest that the inhibition of detrimental proteinase MMP-9 enzyme, allows the body to heal the wound at a quicker rate. The biologics segment held the largest revenue share in 2021 and is projected to expand further at the fastest CAGR during the forecast period. Biologics include growth factors, such as Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF), stem cells, and other anti-diabetic drugs. These agents help reduce hyperglycemia, increase oxygenation & circulation, and repair lost tissues. Therefore, they are increasingly being used for the management of wounds in different stages and are considered to be ideal for DFU treatment. Wound care dressings held the second-largest revenue share, followed by therapy devices and antibiotic medications, in 2021. Industry players are constantly developing new and improved products to ensure quicker healing time for DFU.

 Request a free sample copy or view the report summary: Europe Diabetic Foot Ulcer Treatment Market Report

Europe Diabetic Foot Ulcer Treatment Market Report Highlights

• The neuro-ischemic ulcers segment held the largest market share of 53.10% in 2023 and is expected to continue its dominance over the forecast period.

• The biologics segment dominated the market, with a 36.37% share in 2024, owing to the high demand for biologicals in the treatment of diabetic foot.

• The homecare segment accounted for a share of 52.72% in 2024 and is expected to grow fastest during the forecast period.  The growth of the segment can be attributed to several key factors.

• The diabetic foot ulcer treatment market in Germany is expected to grow owing to the increasing recurrence of foot ulcers in diabetic patients in Germany.

Europe Diabetic Foot Ulcer Treatment Market Segmentation

Grand view research has segmented the Europe diabetic foot ulcer treatment market report based on treatment, type, end-use, and country:

Europe Diabetic Foot Ulcer Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Wound Care Dressings

• Biologics

• Therapy Devices

• Antibiotic Medications

• Others

Europe Diabetic Foot Ulcer Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)

• Neuropathic Ulcers

• Ischemic Ulcers

• Neuro-ischemic Ulcers

Europe Diabetic Foot Ulcer Treatment End-use Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals and Clinics

• Ambulatory Surgical Centers

• Homecare (Others)

Europe Diabetic Foot Ulcer Treatment Country Outlook (Revenue, USD Million, 2018 - 2030)

• UK

• Germany6

• France

• Italy

• Spain

• Denmark

• Sweden

• Norway

List Of Key Players in the Europe Diabetic Foot Ulcer Treatment Market

• ConvaTec Group PLC

• Acelity L.P. Inc.

• 3M Health Care

• Coloplast Corp.

• Smith & Nephew Plc.

• B. Braun SE

• Medline Industries, LP

• Organogenesis, Inc.

• Molnlycke Health Care AB

• Medtronic.